Development of novel theranostics radiopharmaceuticals

We managed to obtain regulatory approval for novel diagnostic radiopharmaceutical ([111In]In-CP04) for personalized diagnosis and therapy of patients with medullary thyroid carcinoma(H2020 GRAN-T-MTC, JTC-TRANSCAN 643638 grants). We found out that 18F-fluorocholine PET/CT imaging was effective for preoperative localization of hyperfunctioning parathyroid tissue. We verified the dosimetry and binding potential of 99mTc-based somatostatin antagonist in murine models(TECANT, ERAPERMED2018-125 grants). We assessed the efficacy and safety of ultrasonographically (US)-guided high-intensity focused ultrasound (HIFU) ablation to treat benign solid thyroid nodules. We also identified the importance of monitoring the iodine supply to prevent iodine deficiency disorders (EUthyroid, H2020 634453 grant).

Projects